Introduction

Chapter
First Online:

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disease of the hematopoietic stem cell (HSC). In its natural history, CML is a tri-phasic disease, presenting predominantly in a chronic phase averaging around 5–7 years, but spanning from between a few months to over 20 years.

Keywords

Chronic Myeloid Leukemia Chronic Myelogenous Leukemia Polycythemia Vera Blast Crisis Chronic Phase Chronic Myeloid Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Piller G. Leukaemia—a brief historical review from ancient times to 1950. Br J Haematol. 2001;112:282-29.Google Scholar
  2. 2.
    Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in ≪ good-risk ≫ chronic granulocytic leukemia. Blood. 1984;63:789-799.Google Scholar
  3. 3.
    Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850-858.Google Scholar
  4. 4.
    Damesek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-375.Google Scholar
  5. 5.
    Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497.Google Scholar
  6. 6.
    Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.Google Scholar
  7. 7.
    Goff SP, Gilboa E, Witte ON, Baltimore D. Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell. 1980;22:777-785.Google Scholar
  8. 8.
    de KA , van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982;300:765-767.Google Scholar
  9. 9.
    Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93-99.Google Scholar
  10. 10.
    Canaani E, Gale RP, Steiner Saltz D, Berrebi A, Aghai E, Januszewicz E. Altered transcription of an oncogene in chronic myeloid leukaemia. Lancet. 1984;1:593-595.Google Scholar
  11. 11.
    Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550-554.Google Scholar
  12. 12.
    Grosveld G, Verwoerd T, van AT , et al. The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript. Mol Cell Biol. 1986;6:607-616.Google Scholar
  13. 13.
    Konopka JB, Watanabe SM, Witte ON . An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 1984;37:1035-1042.Google Scholar
  14. 14.
    Ben Neriah Y, Bernards A, Paskind M, Daley GQ, Baltimore D. Alternative 5’ exons in c-abl mRNA. Cell. 1986; 44:577-586.Google Scholar
  15. 15.
    Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.Google Scholar
  16. 16.
    Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008; 112:4808-4817.Google Scholar
  17. 17.
    Hoglund M, Sandin F, Hellstrom K, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122:1284-1292.Google Scholar
  18. 18.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.Google Scholar
  19. 19.
    Mendizabal AM, Garcia-Gonzalez P, Levine PH. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol. 2013;37:247-254.Google Scholar
  20. 20.
    Bizzozero OJ, Jr, Johnson KG, Ciocco A. Radiation-related leukemia in Hiroshima and Nagasaki, 1946–1964. I. Distribution, incidence and appearance time. N Engl J Med. 1966;274:1095-1101.Google Scholar
  21. 21.
    Landgren O, Goldin LR , Kristinsson SY , Helgadottir EA , Samuelsson J, Bjorkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112:2199-2204.Google Scholar
  22. 22.
    Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. 1993;82:398-407.Google Scholar
  23. 23.
    Sacchi S, Kantarjian HM, O’Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632-2641.Google Scholar
  24. 24.
    Melo JV, Gordon DE, Cross NC, Goldman JM. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood. 1993;81:158-165.Google Scholar
  25. 25.
    Melo J, Deininger MW. Biology of chronic myelogenous leukemia—signaling pathways of initiation and transformation. Hematolol Oncol Clin North Am. 2004;18:545-568.Google Scholar
  26. 26.
    Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356.Google Scholar
  27. 27.
    Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7:441-453.Google Scholar
  28. 28.
    Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657-667.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Timothy P Hughes
    • 1
  • David M Ross
    • 2
  • Junia V Melo
    • 3
  1. 1.SA Pathology, Department of HaematologyCentre for Cancer BiologyAdelaideAustralia
  2. 2.Department of HaematologyFlinders University and Medical Centre and School of Medicine, University of AdelaideAdelaideAustralia
  3. 3.University of Adelaide, Department of HaematologyAdelaideAustralia

Personalised recommendations